ADARx Pharmaceuticals, Inc. (ADRX)

ADARx Pharmaceuticals will go public soon, but the exact IPO date is still unknown.

Stock Price: Pending

IPO price not available yet

ADARx Pharmaceuticals Financials Overview

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Revenue	6.13	3.45	-
Revenue Growth	-	-	-
Gross Profit	6.13	3.45	-
Operating Income	-106.3	-88.37	-58.23
Net Income	-87.87	-73.09	-46.36

Fiscal Year	Current	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Cash & Investments	427.25	480	219.48
Total Debt	6.9	7.74	4.33
Net Cash (Debt)	420.35	472.26	215.15
Net Cash Growth	-	119.50%	-

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Operating Cash Flow	-88.32	262.29	-48.56
Capital Expenditures	-1.89	-2.94	-0.46
Free Cash Flow	-90.21	259.35	-49.02
Free Cash Flow Growth	-	-	-

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Gross Margin	100.00%	100.00%	-
Operating Margin	-1734.98%	-2562.05%	-
Pretax Margin	-1434.14%	-2119.11%	-
Profit Margin	-1434.14%	-2119.11%	-
FCF Margin	-1472.37%	7519.66%	-